INCIDENCE OF SERIOUS GASTROINTESTINAL EVENTS AND INFLAMMATORY BOWEL DISEASE AMONG TILDRAKIZUMAB-TREATED PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: DATA FROM 3 LARGE RANDOMISED CLINICAL TRIALS

被引：1
|
作者：
Gooderham, M. [1 ,2 ]
Elewski, B. E. [3 ]
Pariser, D. M. [4 ,5 ]
Sofen, H. [6 ]
Mendelsohn, A. M. [7 ]
Cichanowitz, N. [8 ]
Li, Q. [8 ]
La Rosa, C. [8 ]
机构：
[1] Prob Med Res, Waterloo, ON, Canada
[2] Skin Ctr Dermatol, Peterborough, ON, Canada
[3] Univ Alabama Birmingham, Sch Med, Dept Dermatol, Birmingham, AL USA
[4] Eastern Virginia Med Sch, Norfolk, VA 23501 USA
[5] Virginia Clin Res Inc, Norfolk, VA USA
[6] Univ Calif Los Angeles, Dept Med Dermatol, Los Angeles, CA USA
[7] Sun Pharmaceut Ind Inc, Princeton, NJ USA
[8] Merck & Co Inc, Kenilworth, NJ USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.6782
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0291
引用
收藏
页码：364 / 364
页数：1
相关论文
共 50 条
  • [1] Incidence of Serious Gastrointestinal Events and Inflammatory Bowel Disease Among Tildrakizumab-Treated Patients with Moderate to Severe Plaque Psoriasis: Data from 3 Large Randomized Clinical Trials
    Gooderham, Melinda
    Elewski, Boni E.
    Pariser, David M.
    Sofen, Howard
    Mendelsohn, Alan M.
    Cichanowitz, Nicole
    Li, Qing
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [2] Incidence of serious gastrointestinal events and inflammatory bowel disease among tildrakizumab-treated patients with moderate-to-severe plaque psoriasis: Data from 3 large randomized clinical trials
    Gooderham, Melinda
    Elewski, Boni
    Pariser, David
    Sofen, Howard
    Mendelsohn, Alan
    Cichanowitz, Nicole
    Li, Qing
    la Rosa, Carmen
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB166 - AB166
  • [3] Incidence of serious gastrointestinal events among tildrakizumab-treated patients with moderate to severe plaque psoriasis: Data from 3 randomized clinical trials
    Gooderham, M.
    Elewski, B.
    Pariser, D.
    Sofen, H.
    Mendelsohn, A.
    Li, Q.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 63 - 63
  • [4] Incidence of cardiovascular events among tildrakizumab-treated patients with moderate-to-severe plaque psoriasis: pooled data from three large randomised clinical trials
    Bissonnette, R.
    Fernandez-Penas, P.
    Puig, L.
    Mendelsohn, A. M.
    Rozzo, S. J.
    Menter, A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (01) : E21 - E24
  • [5] Incidence of cardiovascular events among tildrakizumab-treated patients with moderate to severe plaque psoriasis: Pooled data from 3 large randomized clinical trials
    Bissonnette, Robert
    Fernandez-Penas, Pablo
    Puig, Lluis
    Mendelsohn, Alan M.
    Rozzo, Stephen J.
    Menter, Alan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB79 - AB79
  • [6] INCIDENCE OF SERIOUS GASTROINTESTINAL EVENTS AMONG TILDRAKIZUMAB-TREATED PATIENTS WITH PSORIASIS
    Gooderham, Melinda
    Elewski, Boni E.
    Pariser, David M.
    Sofen, Howard
    Mendelsohn, Alan M.
    Cichanowitz, Nicole
    Li, Qing
    La Rosa, Carmen
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 24 - 24
  • [7] Incidence of serious gastrointestinal events among tildrakizumab-treated patients with psoriasis
    Gooderham, M.
    Elewski, B. E.
    Pariser, D. M.
    Sofen, H.
    Mendelsohn, A. M.
    Rozzo, S. J.
    Li, Q.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (10) : E350 - E352
  • [8] Incidence of cardiovascular events among tildrakizumab-treated patients with psoriasis: Pooled data from 3 large randomized clinical trials
    Bissonnette, R.
    Fernandez-Penas, P.
    Puig, L.
    Mendelsohn, A.
    Rozzo, S.
    Menter, A.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 62 - 62
  • [9] Incidence of cardiovascular events in patients with moderate-to-severe plaque psoriasis treated with tildrakizumab: pooled analysis from a phase 2 and two phase 3 trials
    Bissonnette, R.
    Fernandez-Penas, P.
    Puig, L.
    Peserico, A.
    Fumero, E.
    Mendelsohn, A.
    Rozzo, S.
    Menter, A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 46 - 47
  • [10] NO INCREASED INCIDENCE OF INFLAMMATORY BOWEL DISEASE AMONG SECUKINUMAB-TREATED PATIENTS WITH MODERATE TO SEVERE PSORIASIS, PSORIATIC ARTHRITIS, OR ANKYLOSING SPONDYLITIS: DATA FROM 14 PHASE 2 AND PHASE 3 CLINICAL STUDIES
    Schreiber, S.
    Sands, B. E.
    Deodhar, A.
    Baeten, D.
    Huang, J.
    Gandhi, K.
    Karyekar, C.
    Fox, T.
    Gaillez, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 97 - 98
12345